<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947385</url>
  </required_header>
  <id_info>
    <org_study_id>IDE196-001</org_study_id>
    <nct_id>NCT03947385</nct_id>
  </id_info>
  <brief_title>Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions</brief_title>
  <official_title>A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEAYA Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEAYA Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety&#xD;
      and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11&#xD;
      (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous&#xD;
      melanoma, colorectal cancer, and other solid tumors.&#xD;
&#xD;
      Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics&#xD;
      of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose.&#xD;
      Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the&#xD;
      study.&#xD;
&#xD;
      Phase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of&#xD;
      IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet&#xD;
&#xD;
      Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and&#xD;
      pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine&#xD;
      the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2&#xD;
      (dose expansion) part of the study.&#xD;
&#xD;
      Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and&#xD;
      pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine&#xD;
      the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2&#xD;
      (dose expansion) part of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicity (DLT)</measure>
    <time_frame>28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</time_frame>
    <description>Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</time_frame>
    <description>Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</measure>
    <time_frame>Approx. 6 months</time_frame>
    <description>Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</measure>
    <time_frame>Approx. 6 months</time_frame>
    <description>Pharmacokinetics of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) in Dose Expansion by Blinded Independent Review Committee</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by Blinded Independent Review Committee</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by Investigator</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response by Investigator</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control by Investigator</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Participants with Adverse Events</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Approx. 48 months</time_frame>
    <description>RECIST v1.1</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approx. 48 months</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Metastatic Uveal Melanoma</condition>
  <condition>Cutaneous Melanoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDE196 dosed orally, twice daily (BID) for each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Binimetinib Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Binimetinib Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Crizotinib Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Crizotinib Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet PK Substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDE196 dosed orally, once on Cycle 1 Day 1; thereafter, twice daily (BID) for each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDE196</intervention_name>
    <description>IDE196 dosed orally, twice daily for each 28-day cycle</description>
    <arm_group_label>Dose Escalation Binimetinib Combination</arm_group_label>
    <arm_group_label>Dose Escalation Crizotinib Combination</arm_group_label>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_label>Dose Expansion Binimetinib Combination</arm_group_label>
    <arm_group_label>Dose Expansion Crizotinib Combination</arm_group_label>
    <arm_group_label>Dose Expansion Monotherapy</arm_group_label>
    <arm_group_label>Tablet PK Substudy</arm_group_label>
    <other_name>Protein Kinase C (PKC) Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Binimetinib dosed orally, twice daily for each 28-day cycle</description>
    <arm_group_label>Dose Escalation Binimetinib Combination</arm_group_label>
    <arm_group_label>Dose Expansion Binimetinib Combination</arm_group_label>
    <other_name>MEKTOVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib dosed orally, twice daily for each 28-day cycle</description>
    <arm_group_label>Dose Escalation Crizotinib Combination</arm_group_label>
    <arm_group_label>Dose Expansion Crizotinib Combination</arm_group_label>
    <other_name>XALKORI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be ≥18 years of age&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  MUM: Uveal melanoma with histological or cytological confirmed metastatic&#xD;
                  disease. Or&#xD;
&#xD;
               -  Non-MUM: Advanced cutaneous melanoma, colorectal cancer, or other solid tumor&#xD;
                  that has progressed following prior standard therapies or that has no&#xD;
                  satisfactory alternative therapies and has evidence of GNAQ/11 hotspot mutation&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group ≤1 and expected life expectancy of &gt; 3 months&#xD;
&#xD;
          -  Adequate organ function at screening&#xD;
&#xD;
          -  Adequate contraceptive measures for non-sterilized male and female patients of&#xD;
             childbearing potential&#xD;
&#xD;
        Binimetinib Combination Additional Inclusion Criteria:&#xD;
&#xD;
        • Adequate cardiac function represented by left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
&#xD;
        Crizotinib Combination Additional Inclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy other therapies as applicable or major surgeries must have been&#xD;
             completed at least 4 weeks prior to initiation of crizotinib&#xD;
&#xD;
          -  Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or&#xD;
             lower, prior to initiation of crizotinib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another malignancy&#xD;
&#xD;
          -  Previous treatment with a PKC inhibitor&#xD;
&#xD;
          -  Known MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors&#xD;
&#xD;
          -  Adverse events from prior anti-cancer therapy that have not resolved&#xD;
&#xD;
          -  Untreated or symptomatic central nervous system metastases&#xD;
&#xD;
          -  Human immunodeficiency virus, acquired immunodeficiency syndrome related illness,&#xD;
             hepatitis B virus, or hepatitis C virus&#xD;
&#xD;
          -  Recent surgery or radiotherapy&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Impaired cardiac function&#xD;
&#xD;
          -  For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib,&#xD;
             allergy to mammalian meat products and gelatin&#xD;
&#xD;
        Binimetinib Combination Additional Exclusion Criteria&#xD;
&#xD;
          -  Patient has received prior treatment with a MEK inhibitor&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to first dose&#xD;
&#xD;
          -  History or current evidence of central serous retinopathy (CSR) or retinal vein&#xD;
             occlusion (RVO); History of retinal degenerative disease&#xD;
&#xD;
          -  Concurrent neuromuscular disorders that are associated with elevated creatine&#xD;
             phosphokinase (CPK)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension despite medical treatment&#xD;
&#xD;
          -  Allergy to binimetinib or its components&#xD;
&#xD;
        Crizotinib Combination Additional Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy directly targeting ALK, MET, or ROS1&#xD;
&#xD;
          -  Spinal cord compression&#xD;
&#xD;
          -  Carcinomatous meningitis or leptomeningeal disease&#xD;
&#xD;
          -  History of pneumonitis or interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>IDEAYA Clinical Trials</last_name>
    <phone>+1 650 534 3616</phone>
    <email>IDEAYAClinicalTrials@ideayabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Chmielowski, MD</last_name>
      <email>BChmielowski@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Reeves, MD</last_name>
      <phone>239-274-9930</phone>
      <email>jreeves@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Patel, MD</last_name>
      <phone>727-895-1143</phone>
      <email>vpatel@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mosaic Life Care</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rony Abou-Jawde, MD</last_name>
      <phone>816-271-1301</phone>
      <email>rony.abou-jawde@mymlc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Carvajal, MD</last_name>
      <phone>646-317-6330</phone>
      <email>rdc2150@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Melendez</last_name>
      <email>Sarah.melendez@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Y Perez, BS, CCRP</last_name>
      <email>Cynthia.Perez@jefferson.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>askSARAH</last_name>
      <phone>844-482-4812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Janku, MD</last_name>
      <phone>713-792-6161</phone>
      <email>FJanku@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Carlino, MD</last_name>
      <phone>+61 288 905 200</phone>
    </contact>
    <contact_backup>
      <phone>02 8890 5200</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

